sGalectin-9

GBIOLOGICS is developing next-generation autoimmune therapeutics utilizing sGal-9,
a recombinant protein derived from Galectin-9
which is naturally expressed across diverse immune-related tissues and cell types to modulate biological activity
About

sGal-9 Platform: Proven, Scalable, and Safe

Discovery of Excellent Candidate Substances Applicable to Various Autoimmune Disease Treatments Through Proprietary Technology

High Stability and Activity

Confirmed long-term stability and enhanced activity compared to native Galectin-9

World's First Mass Production Success

Achieved the world’s first successful GMP facility production of Galectin-9

GLP Toxicity Studies

Safety assessment is underway through single-dose and repeated-dose toxicity studies

About
About

Focused Development Strategy for Accelerated Commercialization

Strategic Focus on Autoimmune Diseases with Unmet Needs
and Strong Commercial Viability for Accelerated Development

GB910: Rheumatoid arthritis

An innovative immune therapy for rheumatoid arthritis, an autoimmune disease primarily characterized by chronic synovial inflammation leading to damage of joint cartilage and bone

Learn More

GB930: Lupus

An innovative immune therapy for lupus, a systemic autoimmune disease with high risk of multiple organ damage due to its extensive invasion of various organs in the body

Learn More
About
Terms and Conditions

GBIOLOGICS, Inc.

Address: #3-202, Pangyo Seven Venture Valley Complex 1, 15 Pangyo-ro 228beongil, Bundang-gu, Seongnam-si, Gyeonggi-do 13487

Phone: +82-31-600-7556
FAX: +82-31-600-7555
E-mail: info@gbiologics.com

©2025. GBIOLOGICS, Inc., All Rights Reserved.
contact-section